Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Verve Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VERV
Nasdaq
8731
https://www.vervetx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Verve Therapeutics Inc
After a Serious Setback, Is Verve Therapeutics a Buy?
- Apr 6th, 2024 1:50 pm
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
- Apr 4th, 2024 5:21 pm
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
- Apr 3rd, 2024 5:40 pm
Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects
- Apr 2nd, 2024 8:04 pm
Verve Falls as Gene-Editing Trial Paused on Safety Issues
- Apr 2nd, 2024 1:31 pm
UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
- Apr 2nd, 2024 11:35 am
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
- Apr 2nd, 2024 11:00 am
Verve Therapeutics Announces Updates on its PCSK9 Program
- Apr 2nd, 2024 11:00 am
Verve pauses base editing trial, shifts strategy after treatment side effect
- Apr 2nd, 2024 7:03 am
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Mar 28th, 2024 8:51 pm
3 Stocks That Could Be the Next Big Thing in Gene Editing
- Mar 21st, 2024 8:19 pm
New Forecasts: Here's What Analysts Think The Future Holds For Verve Therapeutics, Inc. (NASDAQ:VERV)
- Feb 29th, 2024 11:12 am
Verve Therapeutics Full Year 2023 Earnings: Beats Expectations
- Feb 28th, 2024 11:00 am
Verve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023
- Feb 28th, 2024 12:02 am
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 27th, 2024 12:30 pm
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
- Feb 19th, 2024 9:08 pm
Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?
- Feb 15th, 2024 8:29 am
3 Gene Editing Stocks With Unprecedented Surge Potential
- Feb 13th, 2024 11:05 am
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
- Feb 12th, 2024 1:30 pm
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Feb 1st, 2024 11:30 am
Scroll